· METHODS:Forty4-6wkBALB-Cmalemiceweighing 20-25gwereused.Thestudygroupsincluded:nondiabeticcontrol (group1),diabeticcontrol (group2), diabeticpropranolol (group3),anddiabeticcelecoxib (group 4). After induction of type 1 diabetes by streptozotocin,propranolol(10 滋g)andcelecoxib(200 滋g dissolvedincarboxymethylcellulose0.5%)wereinjected periocularly.TheocularlevelofVEGFwasmeasuredin allthestudygroupsusingenzyme-linkedimmuno sorbentassay(ELISA)method. [1] .Severalgrowthfactorshave beenidentifiedtobeinvolvedintheprogressionofdiabetic retinopathy.Amongthem,vascularendothelialgrowthfactor (VEGF),whichhasthehighestpotency,isup-regulatedin retinaduringtheearlystagesofdiabeticretinopathy [2] and induceshyper-permeabilityofvesselsandneovascularization [3] . Ithasbeenshownthatprostaglandinsandinparticular prostaglandinE2,whichareincreasedindiabeticratretina, playanimportantroleinthepathogenesisofdiabetic retinopathybyinducingVEGFexpression [4] [5] .Therearetwo distinctenzymesforprostaglandinssynthesis(cyclooxygenase 1and2) [4] .Cyclooxygenase-2,whichisusuallyinduced ininflammatoryconditions,hasbeenshowntohaveamore prominentroleindiabetes [5] [6] .Anon-selective cyclooxygenaseinhibitorsuchasaspirinhasbeenshownto significantlyinhibitthedevelopmentofretinalhemorrhages andacellularcapillariesinadiabeticdogmodel [7] .This indicatesthatcyclooxygenaseinhibitorsmayplayarolein thetreatmentofdiabeticretinopathy.Inthisconcept,therole oforalcelecoxibasaselectivecyclooxygenase-2inhibitorin reducingocularVEGFexpressionhasbeendocumented [8] .
Propranolol,abeta-adrenergicblockingagent,hasbeen showntohavebeneficialtreatmenteffectsininfantile hemangiomasandoxygen-inducedretinopathy [9] [10] . 
DISCUSSION
Duringearlyonsetofdiabeticretinopathy,up-regulationof cyclooxygenase-2occursinretinalcellswhichresultsin prostaglandinE2secretion [11] .Ithasbeenshownthat prostaglandinE2stimulatesVEGFandbasicfibroblast growthfactor(bFGF)expressioninculturedratM俟llercells [4] . Celecoxib,aselectivecyclooxygenase-2antagonistinhibits prostaglandinE2 secretionindiabeticratretina [11] . AyalasomayajulaandKompella [8] reportedthatoralcelecoxib (50mg/kg )inhibitedretinalVEGFmRNAexpression anddecreasedretinalvascularleakageinthediabeticrat model.Inanotherstudy,theyreportedthatcelecoxib-PLGA microparticlescouldsustainretinalcelecoxibdeliveryand inhibitdiabetic-inducedretinaloxidativedamageinarat model [12] .Inourstudy,wesimilarlyfoundthatcelecoxib significantly reducedocularVEGFlevels. However, celecoxibwasadministeredthroughperiocularinjectionin ourstudy. Topicalandsystemicroutesofdrugadministrationare believedtobelesseffectiveindeliveryoftherapeutic amountsofadrugintointraoculartissues.Intravitreal injectionisaccompaniedwithseveralsideeffects,suchas cataracts, endophthalmitis,and retinaldetachment [13] . AyalasomayajulaandKompella [14] showedthatretinal deliveryofcelecoxibwassubstantiallyhigherfollowing subconjunctivaladministrationcomparedtointraperitoneal route.Therefore,perioculardrugadministrationcouldbea promisingalternativetoenhancedrugdeliveryintotheeye [15] . Wealsofoundthatperiocularinjectionofpropranolol significantlydecreasedocularlevelofVEGF.Thisisin contrasttotheresultbyZheng [16] wheretheyshowed thatoralpropranolol( throughdrinkingwatercontaining propranolol)hadnosignificanteffectonretinalVEGF expression.Toourknowledge,nostudyhasinvestigatedthe effectofperiocularpropranololonocularlevelofVEGF.Ina retrospectivecaseseries,Montero [17] showedthat concomitantsystemicbeta-adrenergicblockingagentsmay reducetheneedforrepeatedintravitrealinjectionsof bevacizumabinpatientswithchoroidalneovascularization associatedwithage-relatedmaculardegeneration.The therapeuticeffectofpropranololhasbeenalsodocumentedin oxygen-inducedretinopathy [10] andhemangiomas [18] .The mechanisminvolvedin anti-angiogenesiseffects of propranololisstillnotwellunderstood.Lamy [19] demonstrated thatpropranololinhibited growth factorinducedproliferationofculturedhumanumbilicalvein endothelialcellsinadose-dependentfashionthrougha G0/G1phasecellcyclearrest.StorchandHoeger [9] reviewed themechanismofpropranololoninfantilehemangiomaand indicatedthatearly,intermediateandlong-termeffectsof propranololoninfantilehemangiomacanbeattributedto threedifferentpharmacologicaltargets.Earlyeffects,which areaccompaniedbybrighteningofhemangiomasurface within1-3dafterstartingthetherapy,areattributableto vasoconstrictionsecondarytodecreasedreleaseofnitric oxide.Intermediateeffectsareduetotheblockageof proangiogenicsignals (VEGF,bFGF,metalmatrix proteinase-2/9),whichresultsingrowtharrest.Long-term effectsofpropranololarecharacterizedbyinductionof apoptosisinproliferatingendothelialcells,whichresultsin tumorregression [9] . 
